liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs
Karolinska University Hospital Solna, Sweden.
Karolinska University Hospital Huddinge, Sweden; University of Liverpool, England; University of Strathclyde, Scotland.
Catalan Institute Heatlh, Spain.
Austrian Medical and Medical Dev Agency, Austria.
Show others and affiliations
2013 (English)In: Frontiers in Pharmacology, ISSN 1663-9812, E-ISSN 1663-9812, Vol. 4, article id 39Article in journal (Refereed) Published
Abstract [en]

Background: There are potential conflicts between authorities and companies to fund new premium priced drugs especially where there are safety and/or budget concerns. Dabigatran, a new oral anticoagulant for the prevention of stroke in patients with non-valvular atrial fibrillation (AF), exemplifies this issue. Whilst new effective treatments are needed, there are issues in the elderly with dabigatran due to variable drug concentrations, no known antidote and dependence on renal elimination. Published studies have shown dabigatran to be cost-effective but there are budget concerns given the prevalence of AF. There are also issues with potentially re-designing anticoagulant services. This has resulted in activities across countries to better manage its use. Objective: To (i) review authority activities in over 30 countries and regions, (ii) use the findings to develop new models to better manage the entry of new drugs, and (iii) review the implications for all major stakeholder groups. Methodology: Descriptive review and appraisal of activities regarding dabigatran and the development of guidance for groups through an iterative process. Results: There has been a plethora of activities among authorities to manage the prescribing of dabigatran including extensive pre-launch activities, risk sharing arrangements, prescribing restrictions, and monitoring of prescribing post-launch. Reimbursement has been denied in some countries due to concerns with its budget impact and/or excessive bleeding. Development of a new model and future guidance is proposed to better manage the entry of new drugs, centering on three pillars of pre-, pen-, and post-launch activities. Conclusion: Models for introducing new drugs are essential to optimize their prescribing especially where there are concerns. Without such models, new drugs may be withdrawn prematurely and/or struggle for funding.

Place, publisher, year, edition, pages
FRONTIERS RESEARCH FOUNDATION , 2013. Vol. 4, article id 39
Keywords [en]
critical drug evaluation; dabigatran; demand-side measures; drug and therapeutics committees; managed introduction new medicines; pharmacovigilance; registries; risk sharing
National Category
Pharmacology and Toxicology
Identifiers
URN: urn:nbn:se:liu:diva-141008DOI: 10.3389/fphar.2013.00039ISI: 000347011700038PubMedID: 23717279OAI: oai:DiVA.org:liu-141008DiVA, id: diva2:1142767
Note

Funding Agencies|Karolinska Institutet, Sweden

Available from: 2017-09-20 Created: 2017-09-20 Last updated: 2018-01-13

Open Access in DiVA

fulltext(2300 kB)21 downloads
File information
File name FULLTEXT01.pdfFile size 2300 kBChecksum SHA-512
6cc134353722d14779a8f9a470fa89ee9cfa4e7ebdb31aba77f3b6b3f5b7cbe79d0da108633ee4515beaed04209f6a8de22af2b72c423fb53adddf1fc29934bf
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Hoffmann, Mikael
By organisation
Division of Drug ResearchFaculty of Medicine and Health Sciences
In the same journal
Frontiers in Pharmacology
Pharmacology and Toxicology

Search outside of DiVA

GoogleGoogle Scholar
Total: 21 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 90 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf